Dipraglurant
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine
|
|
Identifiers | |
CAS Number | 872363-17-2 |
ATC code | None |
PubChem | CID: 44557636 |
ChemSpider | 25069676 |
Chemical data | |
Formula | C16H12FN3 |
Molecular mass | 265.285 g/mol |
|
|
|
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics
- Dipraglurant-ER for dystonia - Addex Therapeutics
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Imidazopyridines
- MGlu5 receptor antagonists
- Organofluorides
- Nervous system drug stubs